Xing, Puyuan <br/><br/>
Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.  [electronic resource] 

 -  Thoracic cancer  07 2018 
 - 805-813 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1759-7714 
<br/><br/><label>Standard No.: </label>10.1111/1759-7714.12650  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anaplastic Lymphoma Kinase--genetics<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Brain Neoplasms--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Drug-Related Side Effects and Adverse Reactions--drug therapy<br/>ErbB Receptors--genetics<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Progression-Free Survival<br/>Retrospective Studies